Copper-67 from Iotron Medical
Copper-67 fromIotron Medical

Clinical trials experience

Despite the challenges traditionally associated with copper-67 production a number of highly successful human clinical trials have been performed with antibodies linked to copper-67 payload, demonstrating high response rates, higher tumor uptake and doses, and longer residence time in tumor than alternate radioisotopes. The targeted diseases include Non-Hodgkin Lymphoma (NHL), colon and bladder cancer.

 

In addition, recent work in animal studies has demonstrated the ability of copper radioisotopes to directly target disease including melanoma and glioblastoma.

Click on the links below to access published articles, or contact us for further information:

Iotron Medical, a division of Iotron Industries - providing innovative solutions using electron beam technology for more than 25 years

 

 

Contact us today!

If you have any queries or wish to contact us:


enquiries@copper67.com

 

Print Print | Sitemap
© Iotron Medical Inc 2020